How is the ProQR Therapeutics N.V today?

The ProQR Therapeutics N.V today is trading in the down by 0.00% at 2.16.

How has ProQR Therapeutics N.V performed historically?

The ProQR Therapeutics N.V is currently trading down 0.00% on an intraday basis in the past week the index rose 11.34%. The index has been up 34.16% in the past quarter and rose 30.12% in the past year. You can view this in the overview section.

What is ProQR Therapeutics N.V Annual Revenue?

ProQR Therapeutics N.V Annual Revenue rose 190.22%, in the last year to $18.9 M. Its sector's average revenue growth for the last fiscal year was 8.76%.

What is ProQR Therapeutics N.V Annual Net Profit?

ProQR Therapeutics N.V Annual Net Profit rose 1.27% in the last year to $27.76 M. Its sector's average net profit growth for the last fiscal year was -14.06%.

What is ProQR Therapeutics N.V Price to Earning Ratio?

ProQR Therapeutics N.V Price to Earning Ratio is -6.45, which is negative.

What is ProQR Therapeutics N.V Stock Price?

ProQR Therapeutics N.V Stock Price rose 30.12% and underperformed its sector by 16.76% in the past year.

What is ProQR Therapeutics N.V Quarterly Revenue?

ProQR Therapeutics N.V Quarterly Revenue rose 1.55% YoY to $4.52 M. Its sector's average revenue growth YoY for the quarter was 3.14%.

What is ProQR Therapeutics N.V Quarterly Net profit?

ProQR Therapeutics N.V Quarterly Net profit fell 31.61% YoY to $10.08 M. Its sector's average net profit growth YoY for the quarter was -236.05%.

What is ProQR Therapeutics N.V Debt to Equity Ratio?

ProQR Therapeutics N.V Debt to Equity Ratio of 0.19 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

What is ProQR Therapeutics N.V Return on Equity(ROE)?

ProQR Therapeutics N.V Return on Equity(ROE) for the last financial year was -42.73%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

What is ProQR Therapeutics N.V Mutual Fund Holding?

ProQR Therapeutics N.V Mutual Fund Holding increased by 1.06% in the last quarter to 5.14.

What is ProQR Therapeutics N.V Interest Coverage Ratio?

ProQR Therapeutics N.V Interest Coverage Ratio is -24.96, lesser than one. This means that it is unable to pay interests with its earnings (EBIT).

What is ProQR Therapeutics N.V Institutional Holding?

ProQR Therapeutics N.V Institutional Holding decreased by 3.3% in the last quarter to 40.

MARKETS
SECTOR : PHARMACEUTICALS & BIOTECHNOLOGY
INDUSTRY : MAJOR PHARMACEUTICALS
PROQR THERAPEUTICS N.V

ProQR Therapeutics N.V XNAS: PRQR

ProQR Therapeutics N.V Live Share Price Today, Share Analysis and Chart

Name: ProQR Therapeutics N.V: Is Infosys Ltd. worth buying?
Item: ProQR Therapeutics N.V
Rating: 1.65066675
Author: Trendlyne DVM scores

about

ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The onl...

2.16 0.00 (0.00%)

53.25% Fall from 52W High

536.2K

XNAS Volume

XNAS 26 Jun, 2025 5:30 PM (EDT)

Not Eligible

Expensive Valuation

14.2 / 100

Technically Neutral

51.9 / 100

1Yr Price target upside is 311%

8 analysts

ProQR Therapeutics N.V Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

ProQR Therapeutics N.V Live Share Price Today, Share Analysis and Chart

ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The onl...

53.25% Fall from 52W High

ProQR Therapeutics N.V Live Price Chart

ProQR Therapeutics N.V FAQ

How is ProQR Therapeutics N.V today?

ProQR Therapeutics N.V today is trading in the red, and is down by 0.00% at 2.16.

How has ProQR Therapeutics N.V performed historically?

ProQR Therapeutics N.V is currently trading down 0.00% on an intraday basis. In the past week the stock rose 11.34%. stock has been up 34.16% in the past quarter and rose 30.12% in the past year. You can view this in the overview section.